Warner Pharmaceuticals announced that the controlling shareholder Warner Pharmaceuticals reduced its holdings by 2.632 million shares through a major transaction from September 17, 2026 to September 18, 2026. The implementation of the holdings reduction plan was completed. The transferee was partner Li Mengchun, and the relevant shares were changed from indirect holding to direct ownership. On September 18, 2026, Warner Pharmaceuticals reduced its holdings by another 1.252,000 shares. The total shareholding of Warner Pharmaceuticals and Warner Zhizhen, the total shareholding ratio fell from 508.56,800 shares to 49.60.48 million shares, and the equity change hit a 1% scale; the company's controlling shareholders and actual controllers did not change.

Warner Pharmaceuticals announced that the controlling shareholder Warner Pharmaceuticals reduced its holdings by 2.632 million shares through a major transaction from September 17, 2026 to September 18, 2026. The implementation of the holdings reduction plan was completed. The transferee was partner Li Mengchun, and the relevant shares were changed from indirect holding to direct ownership. On September 18, 2026, Warner Pharmaceuticals reduced its holdings by another 1.252,000 shares. The total shareholding of Warner Pharmaceuticals and Warner Zhizhen, the total shareholding ratio fell from 508.56,800 shares to 49.60.48 million shares, and the equity change hit a 1% scale; the company's controlling shareholders and actual controllers did not change.